|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.(Erratum in CA Cancer J Clin 61: 134, 2011).
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ali SM, Harvey HA and Lipton A: Metastatic
breast cancer: Overview of treatment. Clin Orthop Relat Res.
415(Suppl): S132–S137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bidard FC, Fehm T, Ignatiadis M, Smerage
JB, Alix-Panabières C, Janni W, Messina C, Paoletti C, Müller V,
Hayes DF, et al: Clinical application of circulating tumor cells in
breast cancer: Overview of the current interventional trials.
Cancer Metastasis Rev. 32:179–188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mackey JR, Kerbel RS, Gelmon KA, et al:
Controlling angiogenesis in breast cancer: A systematic review of
anti-angiogenic trials. Cancer Treat Rev. 38:673–688. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ran S, Volk L, Hall K and Flister MJ:
Lymphangiogenesis and lymphatic metastasis in breast cancer.
Pathophysiology. 17:229–251. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carter CL, Allen C and Henson DE: Relation
of tumor size, lymph node status, and survival in 24,740 breast
cancer cases. Cancer. 63:181–187. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Timoshenko AV, Rastogi S and Lala PK:
Migration-promoting role of VEGF-C and VEGF-C binding receptors in
human breast cancer cells. Br J Cancer. 97:1090–1098. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun P, Gao J, Liu YL, Wei LW, Wu LP and
Liu ZY: RNA interference (RNAi)-mediated vascular endothelial
growth factor-C (VEGF-C) reduction interferes with
lymphangiogenesis and enhances epirubicin sensitivity of breast
cancer cells. Mol Cell Biochem. 308:161–168. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Joukov V, Pajusola K, Kaipainen A, Chilov
D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N and Alitalo K: A
novel vascular endothelial growth factor, VEGF-C, is a ligand for
the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
EMBO. 15:290–298. 1996.
|
|
10
|
Valtola R, Salven P, Heikkilä P, Taipale
J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, de Waal R and
Alitalo K: VEGFR-3 and its ligand VEGF-C are associated with
angiogenesis in breast cancer. Am J Pathol. 154:1381–1390. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kinoshita J, Kitamura K, Kabashima A,
Saeki H, Tanaka S and Sugimachi K: Clinical significance of
vascular endothelial growth factor-C (VEGF-C) in breast cancer.
Breast Cancer Res Treat. 66:159–164. 2011. View Article : Google Scholar
|
|
12
|
Chen Z, Varney ML, Backora MW, Cowan K,
Solheim JC, Talmadge JE and Singh RK: Down-regulation of vascular
endothelial cell growth factor-C expression using small interfering
RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and
spontaneous metastasis and enhances survival. Cancer Res.
65:9004–9011. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cai X, Ma S, Gu M, Zu C, Qu W and Zheng X:
Survivin regulates the expression of VEGF-C in lymphatic metastasis
of breast cancer. Diagn Pathol. 7:522012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suzuki A, Ito T, Kawano H, Hayashida M,
Hayasaki Y, Tsutomi Y, Akahane K, Nakano T, Miura M and Shiraki K:
Survivin initiates procaspase 3/p21 complex formation as a result
of interaction with Cdk4 to resist Fas-mediated cell death.
Oncogene. 19:1346–1353. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Altieri DC: Validating survivin as a
cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Altieri DC: Survivin, versatile modulation
of cell division and apoptosis in cancer. Oncogene. 22:8581–8589.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McKenzie JA, Liu T, Goodson AG and
Grossman D: Survivin enhances motility of melanoma cells by
supporting Akt activation and {α}5 integrin upregulation. Cancer
Res. 70:7927–7937. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mehrotra S, Languino LR, Raskett CM,
Mercurio AM, Dohi T and Altieri DC: IAP regulation of metastasis.
Cancer Cell. 17:53–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marioni G, Bertolin A, Giacomelli L,
Marchese-Ragona R, Savastano M, Calgaro N, Marino F, De Filippis C
and Staffieri A: Expression of the apoptosis inhibitor protein
Survivin in primary laryngeal carcinoma and cervical lymph node
metastasis. Anticancer Res. 26:3813–3817. 2006.PubMed/NCBI
|
|
21
|
Kedinger V, Meulle A, Zounib O, et al:
Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral
effect on melanoma subcutaneous xenografts and lung metastases. BMC
Cancer. 13:3382013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ikehara M, Oshita F, Kameda Y, Ito H,
Ohgane N, Suzuki R, Saito H, Yamada K, Noda K and Mitsuda A:
Expression of survivin correlated with vessel invasion is a marker
of poor prognosis in small adenocarcinoma of the lung. Oncol Rep.
9:835–838. 2002.PubMed/NCBI
|
|
23
|
Li X, Dang X and Sun X: Expression of
survivin and VEGF-C in breast cancer tissue and its relation to
lymphatic metastasis. Eur J Gynaecol Oncol. 33:178–182.
2012.PubMed/NCBI
|
|
24
|
Xue M, Ge Y, Zhang J, Liu Y, Wang Q, Hou L
and Zheng Z: Fucoidan inhibited 4T1 mouse breast cancer cell growth
in vivo and in vitro via downregulation of
Wnt/β-catenin signaling. Nutr Cancer. 65:460–468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
National Institutes of Health, Department
of Health and Human Services. Guide for the Care and Use of
Laboratory Animals (Guide) (revised 1985). NIH Publication No.
85–23. (Bethesda). National Institutes of Health. 1989.
|
|
26
|
Xue M, Ge Y, Zhang J, Wang Q, Hou L, Liu
Y, Sun L and Li Q: Anticancer properties and mechanisms of fucoidan
on mouse breast cancer in vitro and in vivo. PloS
One. 7:e434832012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dong XP, Xiao TH, Dong H, Jiang N and Zhao
XG: Endostar combined with cisplatin inhibits tumor growth and
lymphatic metastasis of lewis lung carcinoma xenografts in mice.
Asian Pac J Cancer Prev. 14:3079–3083. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li F, Ambrosini G, Chu EY, Plescia J,
Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and
mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hirakawa S, Brown LF, Kodama S, Paavonen
K, Alitalo K and Detmar M: VEGF-C-induced lymphangiogenesis in
sentinel lymph nodes promotes tumor metastasis to distant sites.
Blood. 109:1010–1017. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Skobe M, Hawighorst T, Jackson DG, Prevo
R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K and Detmar
M: Induction of tumor lymphangiogenesis by VEGF-C promotes breast
cancer metastasis. Nat Med. 7:192–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xia H, Mao Q, Paulson HL and Davidson BL:
siRNA-mediated gene silencing in vitro and in vivo.
Nat Biotechnol. 20:1006–1010. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shim MS and Kwon YJ: Efficient and
targeted delivery of siRNA in vivo. FEBS J. 23:4814–4827.
2010. View Article : Google Scholar
|
|
33
|
Brito LGO, Schiavon VF, Andrade JM, Tiezzi
DG, Peria FM and Marana HR: Expression of Hypoxia-inducible factor
1-α and vascular endothelial growth factor-C in locally advanced
breast cancer patients. Clinics. 66:1313–1320. 2011.PubMed/NCBI
|
|
34
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
West KA, Castillo SS and Dennis PA:
Activation of the PI3K/Akt pathway and chemotherapeutic resistance.
Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Goc A, Al-Husein B, Kochuparambil ST, Liu
J, Heston WW and Somanath PR: PI3 kinase integrates Akt and MAP
kinase signaling pathways in the regulation of prostate cancer. Int
J Oncol. 38:267–277. 2011.PubMed/NCBI
|
